Platinum pharmacokinetics in mice following inhalation of cisplatin dry powders with different release and lung retention properties

Levet, Vincent; Merlos, Romain; Rosière, Rémi; Amighi, Karim; Wauthoz, Nathalie

doi:10.1016/j.ijpharm.2016.12.037

Cited by 22 publications

(42 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many preclinical and clinical studies have demonstrated that the pulmonary route is an efficient administration method in the treatment of various lung diseases like asthma, chronic obstructive pulmonary disease, pulmonary infections and lung cancer (Levet, Merlos, Rosière, Amighi, & Wauthoz, 2017). Inhaled administration of drugs and therapeutic macromolecules has potential as a non-invasive route for systemic or local delivery (Ryan et al, 2015).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Determination of d‐limonene in mice plasma and tissues by a new GC–MS/MS method: Comparison of the pharmacokinetics and tissue distribution by oral and inhalation administration in mice

Chen

Sheng

et al. 2019

Biomedical Chromatography

View full text Add to dashboard Cite

The aim of the present study was to develop a method based on gas chromatography–tandem mass spectrometry (GC–MS/MS) to determine and quantify the d‐limonene in mouse plasma and tissue samples. This new method was validated for the quantification of d‐limonene with the linearity ranges 1.0–1000.0 ng/mL (r2 > 0.9952) for plasma samples and 5.0–5000.0 ng/g (r2 > 0.9940) for tissue samples. The intra‐ and inter‐day assay of precisions in plasma and tissues were <13.4% and the accuracies were within 91.1–105.8%. In the oral/inhalation administration pharmacokinetics and tissue distribution studies, the main pharmacokinetic parameters were the peak concentration = (97.150 ± 34.450)/(4336.415 ± 1142.418) ng/mL, the area under the curve = (162.828± 27.447)/(2085.721 ± 547.787) h ng/mL and the half‐life = (3.196 ± 0.825)/(0.989 ± 0.095) h. The tissue distribution of d‐limonene in mice after oral/inhalation administration demonstrated a decreasing tendency in different tissues (liver > kidney > heart > lung > spleen).

show abstract

Section: Introductionmentioning

confidence: 99%

“…Studies have reported that inhalation administration has an apparent advantage over oral administration in the treatment of certain diseases (Levet et al, 2017;Ryan et al, 2015). More significantly, Wattenberg & Coccia (1991) found that oral administration DL to mice could inhibit carcinogen-induced lung neoplasia.…”

Section: Introductionmentioning

confidence: 99%

Determination of d‐limonene in mice plasma and tissues by a new GC–MS/MS method: Comparison of the pharmacokinetics and tissue distribution by oral and inhalation administration in mice

Chen

Sheng

et al. 2019

Biomedical Chromatography

View full text Add to dashboard Cite

show abstract

“…Therefore, we have chosen to illustrate one development of a dry powder for inhalation that has almost all of the different aspects required to render it technically and clinically applicable (i.e. potentially well-tolerated excipients, a high drug loading and FPF, and using industrial scaling-up techniques with a good production yield) [101][102][103].…”

Section: Controlled-release Formulations With Sustained Lung Retentiomentioning

confidence: 99%

Inhaled cytotoxic chemotherapy: clinical challenges, recent developments, and future prospects

Wauthoz

Rosière

Amighi

2020

Expert Opinion on Drug Delivery

Self Cite

View full text Add to dashboard Cite

Introduction: Since 1968, inhaled chemotherapy has been evaluated and has shown promising results up to phase II but has not yet reached the market. This is due to technological and clinical challenges that require to be overcome with the aim of optimizing the efficacy and the tolerance of drug to reopen new developments in this field. Moreover, recent changes in the therapeutic standard of care for treating the patient with lung cancer also open new opportunities to combine inhaled chemotherapy with standard treatments. Areas covered: Clinical and technological concerns are highlighted from the reported clinical trials made with inhaled cytotoxic chemotherapies. This work then focuses on new pharmaceutical developments using dry powder inhalers as inhalation devices and on formulation strategies based on controlled drug release and with sustained lung retention or based on nanomedicine. Finally, new clinical strategies are described in regard to the impact of the immunotherapy on the patient's standard of care. Expert opinion: The choice of the drug, inhalation device, and formulation strategy as well as the position of inhaled chemotherapy in the patient's clinical care are crucial factors in optimizing local tolerance and efficacy as well as in its scalability and applicability in clinical practice.

show abstract

“…On the other hand, the factors affecting the ultrasonic nebulizers are different as the equipment works on different principles: the temperature of the piezoelectric crystal, the time of nebulization, the addition of buffer, pH and the drug principles [57][58][59][60][61][62]. Dry powder cisplatin has been created and it could be possibly administered as local therapy [63][64][65]. Dry powder has the disadvantage that the particles have two different axis (x,y) and one axis is always larger so they can easily induce cough.…”

Section: Factors Affecting the Production And Depositionmentioning

confidence: 99%

“…Regarding human trials, the administration was performed with jet-nebulizers as a production system and under strict protection measures such as the high efficiency particulate air (HEPA) filter. In the animal studies, the aerosol was administered while the animals were inside a plastic cage or a plexi-glass chamber [28,64,[67][68][69][70][71]. A number of evaluation examinations were utilized in order to check the safety and efficiency of the treatment.…”

Section: Platinum Analogsmentioning

confidence: 99%

Inhaled chemotherapy adverse effects: mechanisms and protection methods

et al. 2019

View full text Add to dashboard Cite

Lung cancer is still diagnosed at a late stage due to a lack of symptoms. Although there are novel therapies, many patients are still treated with chemotherapy. In an effort to reduce adverse effects associated with chemotherapy, inhaled administration of platinum analogs has been investigated. Inhaled administration is used as a local route in order to reduce the systemic adverse effects; however, this treatment modality has its own adverse effects. In this mini review, we present drugs that were administered as nebulized droplets or dry powder aerosols for non-small-cell lung cancer. We present the adverse effects and methods to overcome them.

show abstract

Platinum pharmacokinetics in mice following inhalation of cisplatin dry powders with different release and lung retention properties

Cited by 22 publications

References 32 publications

Determination of d‐limonene in mice plasma and tissues by a new GC–MS/MS method: Comparison of the pharmacokinetics and tissue distribution by oral and inhalation administration in mice

Determination of d‐limonene in mice plasma and tissues by a new GC–MS/MS method: Comparison of the pharmacokinetics and tissue distribution by oral and inhalation administration in mice

Inhaled cytotoxic chemotherapy: clinical challenges, recent developments, and future prospects

Inhaled chemotherapy adverse effects: mechanisms and protection methods

Contact Info

Product

Resources

About